The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma
Date
2019Author
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Tong, Daniel
Engelmann, Bodil
Chamberlain, Florence
Thway, Khin
Fisher, Cyril
Hayes, Andrew
Fotiadis, Nicos
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Miah, Aisha B.
Zaidi, Shane H.
Benson, Charlotte
Graaf, Winette Van Der
Jones, Robin L.
ISSN
0250-70051791-7530
Source
Anticancer ResearchVolume
39Issue
9Pages
4891-4896Google Scholar check
Metadata
Show full item recordAbstract
Background/Aim: Epithelioid haemangioendothelioma (EHE) is a rare tumor with a wide spectrum of clinical behavior. There is no consensus on the role of local therapy in symptomatic, multi-focal disease. Patients and Methods: A retrospective review of patients presenting to the Royal Marsden Hospital between January 2000 and December 2017 was conducted. Results: Fifty-three patients with EHE were identified, of which 18 patients (34.0%) received local therapy, and 11 patients (20.8%) underwent active surveillance. A variety of local treatment modalities were used with few toxicities, and local recurrence was managed with other local treatments or systemic therapy. Distal disease progression was infrequent (n=4, 7.5%). Patients who developed pleural effusion (n=5, 9.4%) had poor outcome irrespective of treatment. Conclusion: Local therapy has a role in a selected patient group managed in a multidisciplinary setting, including patients with indolent disease, and patients with a solitary area of progression/symptomatic disease.